Regeneron Pharmaceuticals And Sanofi Today Announced That National Medical Products Administration In China Has Approved Dupixent (Dupilumab) As An Add-on Maintenance Treatment For Adults With Uncontrolled Chronic Obstructive Pulmonary Disease
Regeneron Pharmaceuticals And Sanofi Today Announced That National Medical Products Administration In China Has Approved Dupixent (Dupilumab) As An Add-on Maintenance Treatment For Adults With Uncontrolled Chronic Obstructive Pulmonary Disease
再生元製藥公司和賽諾菲安萬特今天宣佈，中國國家藥品監督管理局已批准杜璞珊（Dupilumab）作爲一種附加維持治療，用於治療患有難以控制的慢性阻塞性肺疾病的成年人。
Approval follows EU approval of Dupixent for adults with COPD with raised blood eosinophils, and is based on two landmark Phase 3 trials showing Dupixent significantly reduced exacerbations, improved lung function and also improved health-related quality of life.
在歐盟批准Dupixent用於患有慢性阻塞性肺病且血液中嗜酸性粒細胞升高的成年人之後，該批准是基於兩項具有里程碑意義的3期試驗，顯示Dupixent顯著減少了惡化，改善了肺功能，還改善了與健康相關的生活質量。
COPD is the most prevalent chronic respiratory disease in China, and is a priority within the government's Healthy China 2030 public health plan.
慢性阻塞性肺病是中國最流行的慢性呼吸道疾病，也是政府《健康中國2030》公共衛生計劃中的優先事項。
Dupixent is now approved in four indications across respiratory and dermatological diseases in China.
在中國，Dupixent現已獲准用於呼吸道和皮膚科疾病的四種適應症。
資訊熱榜
更新時間